scholarly journals Editorial: proton pump inhibitors, Helicobacter pylori and gastric cancer - the need for long-term follow-up

2016 ◽  
Vol 43 (5) ◽  
pp. 647-648
Author(s):  
E. J. Kuipers
Keyword(s):  
Gastric Cancer ◽  
Helicobacter Pylori ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Long Term Follow Up

scholarly journals Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study

Gut ◽  
2017 ◽  
Vol 67 (1) ◽  
pp. 28-35 ◽  
Author(s):  
Ka Shing Cheung ◽  
Esther W Chan ◽  
Angel Y S Wong ◽  
Lijia Chen ◽  
Ian C K Wong ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Helicobacter Pylori ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Proportional Hazards Model ◽  
Absolute Risk ◽  
Eradication Therapy ◽  
Cox Proportional Hazards ◽  
Cox Proportional Hazards Model

ObjectiveProton pump inhibitors (PPIs) is associated with worsening of gastric atrophy, particularly in Helicobacter pylori (HP)-infected subjects. We determined the association between PPIs use and gastric cancer (GC) among HP-infected subjects who had received HP therapy.DesignsThis study was based on a territory-wide health database of Hong Kong. We identified adults who had received an outpatient prescription of clarithromycin-based triple therapy between year 2003 and 2012. Patients who failed this regimen, and those diagnosed to have GC within 12 months after HP therapy, or gastric ulcer after therapy were excluded. Prescriptions of PPIs or histamine-2 receptor antagonists (H2RA) started within 6 months before GC were excluded to avoid protopathic bias. We evaluated GC risk with PPIs by Cox proportional hazards model with propensity score adjustment. H2RA was used as a negative control exposure.ResultAmong the 63 397 eligible subjects, 153 (0.24%) developed GC during a median follow-up of 7.6 years. PPIs use was associated with an increased GC risk (HR 2.44, 95% CI 1.42 to 4.20), while H2RA was not (HR 0.72, 95% CI 0.48 to 1.07). The risk increased with duration of PPIs use (HR 5.04, 95% CI 1.23 to 20.61; 6.65, 95% CI 1.62 to 27.26 and 8.34, 95% CI 2.02 to 34.41 for ≥1 year, ≥2 years and ≥3 years, respectively). The adjusted absolute risk difference for PPIs versus non-PPIs use was 4.29 excess GC (95% CI 1.25 to 9.54) per 10 000 person-years.ConclusionLong-term use of PPIs was still associated with an increased GC risk in subjects even after HP eradication therapy.

Long‐term follow up of serum pepsinogens in patients with gastric cancer or dysplasia after Helicobacter pylori eradication

2020 ◽  
Vol 35 (9) ◽  
pp. 1540-1548 ◽  
Author(s):  
Gitark Noh ◽  
Nayoung Kim ◽  
Yonghoon Choi ◽  
Hye Seung Lee ◽  
Young Jae Hwang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Helicobacter Pylori ◽  
Helicobacter Pylori Eradication ◽  
Serum Pepsinogens ◽  
Long Term Follow Up

scholarly journals Gastritis: An Update in 2020

2020 ◽  
Vol 18 (3) ◽  
pp. 488-503
Author(s):  
Massimo Rugge ◽  
Kentaro Sugano ◽  
Diana Sacchi ◽  
Marta Sbaraglia ◽  
Peter Malfertheiner
Keyword(s):  
Gastric Cancer ◽  
Helicobacter Pylori ◽  
Cancer Risk ◽  
Staging System ◽  
Patient Specific ◽  
Prognostic Impact ◽  
Follow Up Studies ◽  
Long Term Follow Up

Abstract Purpose of review The gastritis constellation includes heterogeneous clinicopathological entities, among which long-standing, non-self-limiting gastritis, mainly due to Helicobacter pylori infection, has been epidemiologically, biologically, and clinically linked to gastric cancer development (i.e. “inflammation-associated cancer”). This review illustrates the updated criteria applied in the taxonomy of gastritis (Kyoto classification), elucidates the biological rationale for endoscopy biopsy sampling (heterogeneity of gastric mucosa), and finally reports the results of long-term follow-up studies supporting the reliability of biopsy-based gastritis staging as predictor of gastritis-associated cancer risk. Recent findings By assuming gastric atrophy as the “cancerization field” where (non-syndromic) gastric cancer mostly develops, recent long-term follow-up studies consistently demonstrate the prognostic impact of the gastritis OLGA staging system. Summary Helicobacter pylori eradication is the leading strategy in the primary prevention of gastric cancer. In a multidisciplinary dimension of secondary cancer prevention, the OLGA staging system reliably ranks the patient-specific cancer risk, thus providing the clinical rationale for a tailored follow-up strategy.

Change of the grades of atrophy and intestinal metaplasia after helicobacter pylori eradication: long-term follow-up

2000 ◽  
Vol 118 (4) ◽  
pp. A1302-A1303
Author(s):  
Kiichi Satoh ◽  
Ken Kihira ◽  
Hiroshi Kawata ◽  
Keiko Fukazawa ◽  
Satoshi Kawakami ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Intestinal Metaplasia ◽  
Helicobacter Pylori Eradication ◽  
Long Term Follow Up

Long-term follow-up of gastric histology after Helicobacter pylori eradication

1996 ◽  
Vol 11 (7) ◽  
pp. 670-673 ◽  
Author(s):  
GEOFFREY M FORBES ◽  
J ROBIN WARREN ◽  
MARK E GLASER ◽  
DIGBY JE CULLEN ◽  
BARRY J MARSHALL ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Helicobacter Pylori Eradication ◽  
Long Term Follow Up

Long-Term Follow-Up of a Pilot Phase II Study with Neoadjuvant Epidoxorubicin, Etoposide and Cisplatin in Gastric Cancer

Oncology ◽  
2004 ◽  
Vol 67 (1) ◽  
pp. 48-53 ◽  
Author(s):  
C. Barone ◽  
A. Cassano ◽  
C. Pozzo ◽  
D. D’Ugo ◽  
G. Schinzari ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Pilot Phase ◽  
Long Term Follow Up

scholarly journals A Case of Early Gastric Cancer Detected during Long-Term Follow up of Gastric Ulcer Scar

1996 ◽  
Vol 48 (0) ◽  
pp. 180-181
Author(s):  
Yoko Oishi ◽  
Masao Tani ◽  
Seitaku Hayashi ◽  
Fumio Kando ◽  
Naoya Saito ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Gastric Ulcer ◽  
Early Gastric Cancer ◽  
Ulcer Scar ◽  
Long Term Follow Up

scholarly journals Long-term proton pump inhibitor use and the incidence of gastric cancer: A systematic review and meta-analysis

2020 ◽  
Vol 2 (1) ◽  
pp. 1-11
Author(s):  
Ju-Li Lin ◽  
Jian-Xian Lin ◽  
Chao-Hui Zheng ◽  
Jian-Wei Xie ◽  
Jia-bin Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Systematic Review ◽  
Proton Pump Inhibitor ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Meta Analysis ◽  
Inclusion Criteria ◽  
Risk Ratios

Background: There are controverted whether the long-term use of proton pump inhibitors (PPI) will increase the risk of gastric cancer. We performed a meta-analysis to assess the risk of gastric cancer in PPI users compared with non-PPI users. Methods: The main inclusion criteria were original studies reporting the incidence of gastric cancer in PPI users compared with non-PPI users. Key outcomes were the risk ratios (RR) for gastric cancer in association with PPI users or non-PPI users. Results: We analyzed data from 8 studies, comprising more than 927,684 patients. The risk of gastric cancer in PPI users was significantly higher than in non-PPI users [RR= 2.10, 95% CI (1.17-3.97)]. The risk of gastric cancer was similar between the 2 groups when the duration was ≤1 year [RR= 2.18, 95% CI (0.66-7.11)]. While the risk of gastric cancer for PPI users was higher than in non-PPI users when the duration was between 1-3 years, ≥1 year, ≥3 years and ≥5 years. The risk of non-cardiac gastric cancer for PPI users was higher than for non-PPI users [RR= 2.66, 95% CI (1.66 -4.27)], and the risk of non-cardiac gastric cancer for PPI users was higher than for non-PPI users when the duration ≥1 year [RR= 1.99, 95% CI (1.03-3.83)], but the risk for cardiac gastric cancer was similar between the 2 groups [RR= 1.86, 95% CI (0.71-4.89)]. Conclusions: We found the long-term use of PPI (duration ≥1 year) was significantly associated with a higher risk of non-cardiac gastric cancer.

Long-term follow-up of patients with low-grade gastric MALT lymphoma after eradication of helicobacter pylori

2000 ◽  
Vol 118 (4) ◽  
pp. A764
Author(s):  
In Sung Song ◽  
You Sun Kim ◽  
Il Ju Choi ◽  
Joo Sung Kim ◽  
Hyun Chae Jung ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Malt Lymphoma ◽  
Gastric Malt Lymphoma ◽  
Low Grade ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document